At 4.1% CAGR, the Europe Endothelial Dysfunction Market is Projected to be Worth US$ 776.37 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Europe endothelial dysfunction market was valued at US$ 611.28 million in 2022 and is expected to reach US$ 776.37 million by 2028, registering a CAGR of 4.1% from 2022 to 2028. Increasing incidences of cardiovascular diseases and rising incidences of high cholesterol, diabetes and obesity are the critical factors attributed to the Europe endothelial dysfunction market expansion.                     

Examining endothelial function can improve risk stratification, improve early disease detection, and assess vascular response to therapeutic interventions. There are studies to understand the pathophysiological mechanisms underlying endothelial dysfunction and atherosclerosis progression in a better way and identify new biomarkers and therapeutic strategies to prevent endothelial dysfunction and atherosclerosis to reduce the risk of developing coronary artery disease (CAD) and related complications. Using liquid biopsies and new molecular biology techniques has enabled the identification of a growing list of molecular and cellular markers of endothelial dysfunction that have provided insight into the molecular basis of atherosclerosis as well as potential biomarkers and therapeutic targets for the prevention and treatment of atherosclerosis and CAD.

Research on biomarkers and their clinical application has increased exponentially over the last few decades. Invaluable insight into the pathophysiology of atherosclerosis and the development of novel therapies have been provided by systemic biomarkers. Endothelial dysfunction and inflammation play a central role in the development and progression of CAD. Inflammatory mediators are secreted by inflammatory and vascular cells in atherosclerotic plaque or by organs such as the liver or adipose tissue. Therefore, several inflammation-related factors are considered biomarkers for the early prediction of coronary artery disease. Clinical studies have extensively examined acute phase proteins, cytokines, adhesion molecules, and microparticles as endothelial dysfunction and inflammation markers.

On the contrary, disadvantages associated with the techniques for screening of endothelial dysfunction hurdles the growth of Europe endothelial dysfunction market.

Based on cause, the Europe endothelial dysfunction market is segmented into hypertension, hypercholestrolaemia, obesity, diabetes, behcet's disease, and others. The hypertension segment held 32.8% share of Europe endothelial dysfunction market in 2022, amassing US$ 200.71 million. It is projected to garner US$ 262.23 million by 2028 to expand at 4.6% CAGR during 2022–2028.

Based on test type, the Europe endothelial dysfunction market is segmented into invasive test and non-invasive test. The invasive test segment held 73.9% share of Europe endothelial dysfunction market in 2022, amassing US$ 451.80 million. It is projected to garner US$ 565.80 million by 2028 to expand at 3.8% CAGR during 2022–2028. The non-invasive test segment is further subsegmented into flow mediated dilatory, peripheral arterial tonometry (PAT), venous occlusion pletismography, circulating markers, and others.

Based on end user, the Europe endothelial dysfunction market has been categorized into hospitals, diagnostic centers, clinics, and others.  The hospitals segment held 52.1% share of Europe endothelial dysfunction market in 2022, amassing US$ 318.43 million. It is projected to garner US$ 412.44 million by 2028 to expand at 4.4% CAGR during 2022–2028.    

Based on country, the Europe endothelial dysfunction market has been categorized into the UK, Germany, Italy, France, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.2% share of Europe endothelial dysfunction market in 2022. It was assessed at US$ 178.57 million in 2022 and is likely to hit US$ 237.54 million by 2028, exhibiting a CAGR of 4.9% during 2022–2028.      

Key players operating in the Europe endothelial dysfunction are ZOLL Medical Corp, Sphingo Tec GmbH, The Polymath Co, SMART Medical Ltd, Alam Medical SaRl, and Medizinische Messtechnik GmbH, among others.    

• In July 2020, SphingoTec launched point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction. The company launched its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com